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Recent studies have shown that TNF/cachectin, a cytokine mostly released by ac-
tivated macrophages, plays a central role in experimental cerebral malaria (CM),
an acute and lethal neurological syndrome that follows infection by Plasmodium ber-
ghei ANKA strain in mice (1). This experimental syndrome reproduces some of the
features of human cerebral malaria, the most severe complication of P. falciparum
infection in man. Experimental CM appears to represent a strictly T cell-depen-
dent immunopathological complication of P. berghei infection, since the functional
integrity of CD4+ T lymphocytes is required for the neurological syndrome to occur
(2). IL-3 and granulocyte/macrophage colony-stimulating factor (GM-CSF) are two
cytokines released by activated T cells that stimulate the growth and differentiation
of various hemopoietic cell lines, among which are macrophages (3-5). This work
explores the possible role of these cytokines as intermediates in the marked TNF
release leading to CM .
Materials and Methods
Mice.
￿
Female 8-wk-old CBA/Ca mice, originallyobtained from Bomholtgard, Denmark,
and bred in our animal facilities, were used throughout the experiments.
Infection.
￿
Malaria infection was initiated by asexual blood stages of the parasite, i.e., by
intraperitoneal injection of 106 P . berghei ANKA (PbA)-infected erythrocytes, following the
previously described procedure (2).
Anti-IL-3 and Anti-GM-CSF Antibodies.
￿
On day 3 of infection, mice received either anti-
recombinant mouse IL-3 IgG (five mice), anti-recombinant mouse GM-CSF IgG (10 mice),
or a combination of both antibodies (15 mice), and as controls, IgG fractions of the same
rabbits aftertheir depletion of anti-IL-3 and anti-rGM-CSF antibodies by affinity chroma-
tography (see below) (10 mice). All antibody fractions were obtained through repetitive im-
munization of rabbits and were purified by affinity chromatography usingpurified rIL-3 (4)
or rGM-CSF (6) (kindly provided by Drs. GeoffSchrimcher andJohn DeLamarter, Biogen,
Cambridge, MA) coupled to Afligel 15 (Bio-Rad Laboratories, Richmond, CA), ultracen-
trifuged at 150,000 g for 150 min, and injected intravenously at the dose of 600 Wg in 0.3
ml sterile PBS 0.01 M, pH 7.2. 1 ug of immuno-affinity-purified IgG or 10 ug of protein
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A IgG fraction of the anti-IL-3 antibody were able to inhibit the activity of 2.7 U of native
IL-3 or 10-30 U of rIL-3 . 1 wg immuno-affinity-purified IgG or 10 ilg of protein A IgG frac-
tion of the anti-GM-CSF antibody were able to inhibit 103 U of recombinant GM-CSF.
These determinations were performed using the cell linesdescribed for the cytokine bioassays.
HematologicalStudies.
￿
RBC counts were performed in an improved Neubauer hematocytom-
eter (Assistent, Altnau, Switzerland) after a 1:1,000 dilution of retroorbital blood in PBS.
Parasitemia levels were evaluated on Giemsa-stained smears.
Bioassaysfor Cytokines.
￿
Serum TNF activity was determined using the L929 bioassay (7).
Serum IL-3 and GM-CSF activitieswere explored by studying serial dilutions ofserum from
infected animals for theirability to support growth ofFDCP-1 (8) as described by Ihle et al. (9).
Cell growth was colorimetrically estimated according to Mosmann (10).
HistopathologicalStudies.
￿
Mice presenting neurological signsafterPbA infection were killed
by cervical dislocation. Spleens were harvested and snap-frozen in liquid nitrogen and mac-
rophage staining was revealed using histochemical staining for acid phosphatases.
Results and Discussion
Four groups of CBA/Ca mice, genetically susceptible to CM, were infected with
PbA. 3 d later, these animals were treated with either rabbit anti-mouse rIL-3,
anti-mouse rGM-CSF, a combination ofboth antibodies, or nonimmune rabbit IgG
as controls. Fig. 1 shows the cumulative incidence ofCM in these mice. While each
antibody injected separately had no significant effect, the combined treatment dra-
matically reduced the incidence of the neurological syndrome (13% : two mice pre-
senting CM among 15 treated mice). The protected mice had low or undetectable
serum TNF levels (0.20 t 0.13 ng/ml, n = 15), in contrast to what is observed in
CM (4.98 t 2 .15 ng/ml, n = 6) (1) . As was also observed in the case of prevention
of CM by antiTNF antibodies, the combined anti-rIL-3 anti-rGM-CSF antibody
treatment had no effect on the progression of parasitaemia (data not shown). As
a consequence of this beneficial effect on the development of CM in mice after
P. berghei infection, the survival of mice receiving the dual treatment with anti-IL-3
and anti-GM-CSF was significantly prolonged. These mice died during the third
week of infection, with severe anemia and overwhelming parasitaemia, but without
neurological lesions (Fig. 2) .
It had been previously noted that murine malaria is associatedwith an accumula-
tion ofmacrophages in lymphoid organs (11) and that, in mice with CM, such mac-
rophage infiltration was more important than that observed in malaria-infected mice
without the neurological syndrome (1). Since injections of rIL-3 and rGM-CSF in
the mouselead to an increased monocytosis and accumulation ofmacrophages, notably
in the peritoneal cavity (3, 4), the possibility that antibodies against these cytokines
may decrease the macrophage infiltration observed in CM was explored. On spleen
no treatment
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FIGURE 1.
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Cumulative incidence of the neuro-
logical syndrome (cerebral malaria, CM). Per-
centages ofmice presentingclinical and histolog-
ical evidence of neurological involvement were
evaluated during PhA infection. Clinical signs oc-
curred between day 7 and 10 of infection, and
the most frequentlyobserved were haemiparesis,
paraparesis, ataxia, and convulsions. Histopatho
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sections of mice with CM stained for acid phosphatases, it can be seen that macro-
phage infiltration is diffuse through the white and red pulp (Fig. 3 A). Spleen sec-
tions of mice protected by the double antibody treatment (Fig. 3 B) showed that,
while macrophages in the red pulp were significantly more abundant than irk normal,
non infected mice (Fig. 3 C), the diffuse macrophage infiltration of the white pulp
observed in mice developing CM was almost entirely prevented. Thus, it appears
that an extensive macrophage accumulation resulting from the combined effects of
IL-3 and GM-CSF (probably locally released during CM, since when using a bio-
assay (9), no activity was detectable in the serum) may be, at least in part, respon-
sible for the high TNF blood level essential in the development of CM.
The data presented here suggest that IL-3 and GM-CSF are required for the in-
creased in vivo TNF production associated with experimental CM. While the present
and previous studies emphasize the roles played by CD4+ T lymphocyte activation,
macrophage accumulation, and release of IL-3, GM-CSF, and TNF in the occur-
rence of CM, other cell types and cytokines are likely to be involved in this complex
pathogenic pathway. T lymphocytes are the only physiological source of IL-3 identified
so far, but GM-CSF can also be produced, among other cells, by endothelial cells,
in particular under stimulation by TNF (12, 13), suggesting the possibility of an
autoamplifying mechanism. It has been proposed that endothelial cell alterations
induced by TNF are involved in the pathogenesis of the neurovascular lesions typ-
ical of murine CM (1). Furthermore, the increased release of TNF in CM does not
result simply from a quantitatively excessive accumulation of macrophages, as seen
in the lymphoid organs. Stimulation of macrophages by IFN-y, another Cytokine
released by activated T cells, is also required, as suggested by the observation that
treatment PbA-infected mice with anti-IFN-y antibodies prevent the increased TNF
release and CM (Grau et al., manuscript in preparation). These data suggest that
a cytokine cascade is involved in the pathogenesis ofexperimental CM. IFN-y, among
other actions, can activate macrophages and increase the TNF gene transcription
(14), whereas IL-3 and GM-CSF act, at least in part, by increasing the accumula-
tion of macrophages, thus contributing to the elevated serum level of TNF and its
consequences. It should be mentioned that GM-CSF is also known to activate var-
ious macrophage functions (15) and that IL-3 and GM-CSF have been reported to
lead to TNF release by human monocytes (16).
In man, neuropathological complications of malaria are the most common clin-
ical presentation and cause ofdeath in servere Plasmodium falciparum malaria (17-19).1502
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 4 _.0 a enThe precise pathogenic mechanisms of human CM and their possible resemblance
to those of experimental mouse CM remain to be defined.
Summary
IL-3 and granulocyte/macrophage colony stimulating factor (GM-CSF) are two
cytokines released by activated T lymphocytes that stimulate the growth and differen-
tiation of various hematopoietic cell lines, among which are macrophages. It has
been shown that TNF/cachectin, another cytokine that is released mostly by acti-
vated macrophages, plays a central role in experimental cerebral malaria (CM), an
acute and lethal neurological syndrome induced by Plasmodium berghei ANKA infec-
tion in CBA mice. Since CM requires functional CD4' T lymphocytes to occur,
we explored, by injecting rabbit antibodiesto murine rIL-3 and/or GM-CSF, whether
these cytokines are intermediates in the marked TNF release leading to CM. Treat-
ment ofinfected mice with each antibody separatelyhad no protective effect. In con-
trast, when both anti-rGM-CSF and anti-rIL-3 antibodies were injected together;
(a) the occurrence of neurological syndrome was prevented in 90% of the cases; (b)
the rise in serum TNF was prevented; and (c) macrophage accumulation in the spleen
was significantly reduced. Murine CM appears to involve a cytokine cascade in which
IL-3 and GM-CSF lead to the accumulation of TNFreleasing macrophages in vivo.
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